Phospho-AKT (Thr308) antibodies are essential tools for studying the activation status of AKT (Protein Kinase B), a central serine/threonine kinase in the PI3K/AKT/mTOR signaling pathway. AKT regulates critical cellular processes, including survival, proliferation, and metabolism. Its activation requires phosphorylation at two key residues: Thr308 in the catalytic domain and Ser473 in the regulatory domain. Phosphorylation at Thr308. mediated by PDK1 (3-phosphoinositide-dependent protein kinase 1), is necessary for AKT’s enzymatic activity, while Ser473 phosphorylation (often by mTORC2) stabilizes its active conformation.
Antibodies targeting phospho-Thr308 specifically detect AKT only when phosphorylated at this site, enabling researchers to assess pathway activation in response to growth factors, insulin, or other stimuli. These antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to study AKT signaling dynamics in diseases such as cancer, diabetes, and neurodegenerative disorders. In cancer research, elevated phospho-AKT (Thr308) levels are associated with tumor progression, therapy resistance, and poor prognosis, making it a biomarker for hyperactive PI3K/AKT signaling.
When using these antibodies, proper sample preparation (e.g., inclusion of phosphatase inhibitors) and controls (e.g., total AKT and activation stimuli) are critical to avoid artifacts. Cross-reactivity with phosphorylated residues in related kinases should be ruled out via validation assays. Commercial antibodies often specify applications and species reactivity, which must be verified for experimental systems.